Evidence for tissue angiotensin-converting enzyme in explanted hearts of ischemic cardiomyopathy using targeted radiotracer technique

Journal of Nuclear Medicine

Volumn 48, Issue 2, 2007, Pages 182-187

  Dilsizian, Vasken ^a   Eckelman, William C ^b   Loredo, Maria L ^c   Jagoda, Elaine M ^d   Shirani, Jamshid ^e  

^a UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^b Molecular Tracer LLC   (United States)

^c UNIVERSIDAD PANAMERICANA   (Mexico)

^d NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

^e GEISINGER MEDICAL CENTER   (United States)

Author keywords

Angiotensin receptor; Angiotensin converting enzyme; Chymase; Heart failure; Radionuclide imaging; Remodeling

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; CHYMASE; COLLAGEN; DIPEPTIDYL CARBOXYPEPTIDASE; FLUOROBENZOYLLISINOPRIL F 18; LISINOPRIL; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; TRACER; UNCLASSIFIED DRUG; 18F FLUOROBENZOYL LISINOPRIL; 18F-FLUOROBENZOYL-LISINOPRIL; DIAGNOSTIC AGENT; DRUG DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

ARTICLE; AUTORADIOGRAPHY; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LOCALIZATION; EXPLANT; HEART LEFT VENTRICLE INFARCTION; HEART MUSCLE FIBROSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VITRO STUDY; ISCHEMIC HEART DISEASE; LUMINESCENCE; MALE; MAST CELL; PRIORITY JOURNAL; RADIOACTIVITY; SYNTHESIS; ENZYMOLOGY; HEART MUSCLE; HEART MUSCLE ISCHEMIA; METABOLISM;

ANGIOTENSIN II; AUTORADIOGRAPHY; CHYMASES; COLLAGEN; HUMANS; IMMUNOHISTOCHEMISTRY; LISINOPRIL; MALE; MAST CELLS; MYOCARDIAL ISCHEMIA; MYOCARDIUM; PEPTIDYL-DIPEPTIDASE A; RADIOPHARMACEUTICALS; RECEPTOR, ANGIOTENSIN, TYPE 1;

EID: 33846913780     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Bohm M, Kilter H, Kindermann M. Mechanisms contributing to the progression of left ventricular dysfunction to end-stage heart failure. Eur Heart J Suppl. 2003;5(suppl 1):14-21.
2. Hirsch AT, Talsness CE, Schunkert H, et al. Tissue-specific activation of cardiac angiotensin converting enzyme in experimental heart failure. Circ Res. 1991;69:475-482.
3. Konstam MA, Rousseau MF, Kronenberg MW, et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators. Circulation. 1992;86:431-438.
4. Brunner-La Rocca HP, Vaddadi G, Esler MD. Recent insight into therapy of congestive heart failure: focus on ACE inhibition and angiotensin-II antagonism. J Am Coll Cardiol. 1999;33:1163-1173.
5. Tschope C, Schultheiss HP, Walther T. Multiple interactions between the reninangiotensin and the kallikrein-kinin systems: role of ACE inhibition and AT1 receptor blockade. J Cardiovasc Pharmacol. 2002;39:478-487.
6. Lindpaintner K, Lu W, Niedermajer N, et al. Selective activation of cardiac angiotensinogen gene expression in post-infarction ventricular remodeling in the rat. J Mol Cell Cardiol. 1993;25:133-143.
7. Dzau VJ, Re R. Tissue angiotensin system in cardiovascular medicine: a paradigm shift? Circulation. 1994;89:493-498.
8. Hwang DR, Eckelman WC, Mathias CJ, Petrillo EW Jr, Lloyd J, Welch MJ. Positron-labeled angiotensin-converting enzyme (ACE) inhibitor: fluorine-18-fluorocaptopril - probing the ACE activity in vivo by positron emission tomography. J Nucl Med. 1991;32:1730-1737.
9. 18F]fluorobenzoyl lisinopril: a radioligand for angiotensin converting enzyme (ACE) imaging with positron emission tomography. J Labelled Compds Radiopharm. 2001;44(suppl):S268-S270.
10. Cushman DW, Wang FL, Fung WC, Harvey CM, DeForrest JM. Differentiation of angiotensin-converting enzyme (ACE) inhibitors by their selective inhibition of ACE in physiologically important target organs. Am J Hypertens. 1989;2:294-306.
11. Hooper NM, Turner AJ. An ACE structure. Nat Struct Biol. 2003;10:155-157.
12. Moskowitz DW. From pharmacogenomics to improved patient outcomes: angiotensin I-converting enzyme as an example. Diabetes Technol Ther. 2002;4:519-532.
13. Shirani J, Lee J, Quigg RJ, Pick R, Bacharach SL, Dilsizian V. Relation of thallium uptake to morphologic features of chronic ischemic heart disease: evidence for myocardial remodeling in non-infarct myocardium. J Am Coll Cardiol. 2001;38:84-90.
14. Lang L, Jagoda E, Schmall B, et al. Development of fluorine-18-labeled 5-HT1A antagonists. J Med Chem. 1999;42:1576-1586.
15. Weber KT, Brilla CG. Pathologic hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation. 1991;83:1849-1865.
16. Jagoda EM, Lang L, Tokugawa J, et al. Development of 5-HT1A receptor radio-ligands to determine receptor density and changes in endogenous 5-HT. Synapse. 2006;59:330-341.
17. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling: concepts and clinical implications - a consensus paper from an international forum on cardiac remodeling. J Am Coll Cardiol. 2000;35:569-582.
18. Harada K, Sugaya T, Murakami K, Yazaki Y, Komuro I. Angiotensin II type 1A receptor knockout mice display less left ventricular remodeling and improved survival after myocardial infarction. Circulation. 1999;100:2093-2099.
19. Brilla CG, Funck RC, Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation. 2000;102:1388-1393.
20. Schuster DP, McCarthy TJ, Welch MJ, Holmberg S, Sandiford P, Markham J. In vivo measurements of pulmonary angiotensin-converting enzyme kinetics. II. Implementation and application. J Appl Physiol. 1995;78:1169-1178.
21. Markham J, McCarthy TJ, Welch MJ, Schuster DP. In vivo measurements of pulmonary angiotensin-converting enzyme kinetics. I. Theory and error analysis. J Appl Physiol. 1995;78:1158-1168.
22. Sun Y, Mendelsohn FA. Angiotensin converting enzyme inhibitor in heart, kidney, and serum studied ex vivo after administration of zofenopril, captopril, and lisonopril. J Cardiovasc Pharmacol. 1991;18:478-486.
23. Chai SY, Mendelsohn FA, Paxinos G. Angiotensin converting enzyme in rat brain visualized by quantitative invitro autoradiography. Neuroscience. 1987;20:615-627.
24. Rajagopalan R, Kuntz RR, Sharma U, Volkert WA, Pandurangi RS. Chemistry of bifunctional photoprobes. 6. Synthesis and characterization of high specific activity metalated photochemical probes: development of novel rhenium photoconjugates of human serum albumin and Fab fragments. J Org Chem. 2002;67:6748-6757.
25. Balcells E, Meng QC, Johnson WH Jr, Oparil S, Dell'Italia LJ. Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations. Am J Physiol. 1997;273:H1769-H1774.
26. Matsumoto T, Wada A, Tsutamoto T, Ohnishi M, Isono T, Kinoshita M. Chymase inhibition prevents cardiac fibrosis and improves diastolic dysfunction in the progression of heart failure. Circulation. 2003;107:2555-2558.